India Business Opportunities Shadowed By Country's Evolving IP Laws
This article was originally published in The Pink Sheet Daily
Executive Summary
Implementation of intellectual property protections continues to weigh on India's burgeoning pharmaceutical industry.
You may also be interested in...
Indian Pharma Focusing On R&D, Licensing – Ranbaxy Exec
Indian firms are flush with cash and looking to move from generic drugs to proprietary compounds, Ranbaxy’s Shyam Bishen tells “The Pink Sheet” DAILY.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.